

RECEIVED

DEC 10 2001

TECH CENTER 1600 2900

PATENT APPLICATION

Atty. Docket No. 28110/36120A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chadwick et al.

Serial No: 09/905,744

Filed: July 13, 2001


For: Methods and Compositions Relating  
to CD39-Like Polypeptides and Nucleic  
Acids

Group Art Unit: 1644

Examiner: A. DeCloux

) I hereby certify that this paper is being  
) deposited with the United States Postal  
) Service as First Class Mail, postage  
) prepaid in an envelope addressed to:  
) Commissioner for Patents, Washington,  
) D.C. 20231, on this date:

) October 23, 2001

)   
) Nicole Burmeister

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, the attached form PTO-1449 is hereby submitted by Applicants for consideration in connection with the above-identified patent application. Pursuant to 37 C.F.R. § 1.98(d), Applicants are not submitting copies of the listed documents because they were previously submitted to the Patent Office in an earlier application, U.S.S.N. 09/240,639, which is identified in the attached form PTO-1449 and is relied on for an earlier effective filing date under 35 U.S.C. § 120. The information disclosure statement submitted in this earlier application complies with 37 C.F.R. § 1.98(a)-(c). Copies of any listed documents will be resubmitted at the Examiner's request.

Enclosed is a copy of the International Search Report in an application owned by the assignee of this application, Hyseq, Inc. (International Application Number PCT/US99/16180, filed July 16, 1999).


This Information Disclosure Statement is not intended to be an admission that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. § 102 or § 103.

Because this Information Disclosure Statement is being submitted before the mailing of a first office action on the merits under 37 C.F.R. § 1.97(b)(2), no fees are thought to be due. However, should any fees be deemed due, please charge any such fees to Marshall, Gerstein & Borun's Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By:

  
Michael F. Borun  
Registration No. 25,447  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

October 23, 2001